Is the therapeutic effect and efficacy of erdafitinib good?

Erdafitinib (Erdafitinib), as a new type of targeted therapy, has received widespread attention in the field of urinary system malignancies, especially locally advanced or metastatic urothelial cancer (bladder cancer) due to its precise efficacy against specific gene mutations. Its development is based on in-depth research on the fibroblast growth factor receptor (FGFR) signaling pathway. This pathway is abnormally active in some tumor cells and is closely related to the growth and spread of tumors. Erdafitinib achieves anti-cancer effects by selectively inhibiting FGFR subtypes and blocking the growth signals of tumor cells. It is especially suitable for patients with FGFR2 or FGFR3 gene mutations.

From the perspective of efficacy, the outstanding advantage of erdafitinib is that it has a clear target and only acts on patients with corresponding molecular characteristics, thus improving the pertinence and response rate of treatment. Compared with traditional chemotherapy or immunotherapy, it can not only reduce tumor size, but also potentially delay disease progression and provide patients with longer progression-free survival. However, the premise of this efficacy is that patients must undergo genetic testing to confirm the presence of FGFR-related mutations or fusions in their tumors, otherwise the drug may not be effective. Therefore, in practical clinical applications, erdafitinib is often used in conjunction with molecular diagnostic tools to ensure accurate medication.

In addition, the oral dosage form of erdafitinib also brings a more convenient treatment method to patients, avoiding the trouble of frequent hospitalization for infusion and improving treatment compliance. Although its side effects such as hyperphosphatemia and eye discomfort require regular monitoring and timely intervention, the overall safety is still considered controllable, especially under the close guidance of doctors, and patients can usually successfully complete the entire treatment cycle.

Currently, erdafitinib has been approved by regulatory agencies in many countries for specific types of urothelial cancer, and has been gradually expanded to other studies on FGFR mutation-related tumors. Its global use experience shows that this drug has broad prospects in the field of precision medicine.

Reference materials：https://www.balversa.com/